Merck (NYSE: MRK) announced that its Phase 3 KEYNOTE-C93 trial evaluating Keytruda (pembrolizumab) as monotherapy met its primary endpoint of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE